

CLAIMS

1. A recombinant modified vaccinia virus Ankara (MVA) comprising at least one nucleotide sequence encoding an antigenic determinant of a respiratory syncytial virus (RSV) membrane glycoprotein F encoding at least one of the amino acid sequences of SEQ ID NO:4, 6 and 16 and at least one nucleotide sequence encoding the amino acid sequence of SEQ ID NO:18, SEQ ID NO:33 and SEQ ID NO:10.
2. A recombinant modified vaccinia virus Ankara (MVA) of claim 1, wherein the at least one nucleotide sequence encoding an antigenic determinant of the respiratory syncytial virus (RSV) membrane glycoprotein F comprises the nucleotide sequence of SEQ ID NO:5.
3. The recombinant MVA of claims 1 - 2, wherein the nucleotide sequence encoding the amino acid sequence of SEQ ID NO:18 comprises the nucleotide sequence of SEQ ID NO:17.
4. The recombinant MVA of claims 1 - 3 further comprising at least one nucleotide sequence encoding an antigenic determinant of an RSV G membrane glycoprotein.
5. The recombinant MVA of claim 4, wherein the nucleotide sequence encoding an antigenic determinant of the RSV G membrane glycoprotein is derived from RSV strain A, preferably from strain A2, and/or B.
6. The recombinant MVA of claims 4 - 5, wherein the nucleotide sequence encoding an antigenic determinant of the RSV G membrane glycoprotein comprises a nucleotide sequence encoding the amino acid sequence selected from SEQ ID NO:2 and 8.
7. The recombinant MVA of claims 4 - 5, wherein the nucleotide sequence encoding an antigenic determinant of the RSV G membrane glycoprotein comprises the nucleotide sequence selected from SEQ ID NO:1 and 7.
8. The recombinant MVA of claims 4 - 5, further comprising an antigenic determinant of a second RSV G membrane glycoprotein.
9. The recombinant MVA of claims 1 - 8, comprising a nucleotide sequence encoding an antigenic determinant comprising SEQ ID NO:1 and 7 or encoding the amino acid sequence of SEQ ID NO: 2 and 8.
10. A pharmaceutical composition and/or vaccine comprising the recombinant MVA of claims 1 - 9 and, optionally, a pharmaceutically acceptable carrier and/or diluent.